Sunitinib Plus Nivolumab for Patients With Advanced Extraskeletal Myxoid Chondrosarcoma
According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
These data were first presented by Nadia Hindi, Fundación Jimenez Diaz University Hospital, Madrid, Spain, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
In this study, 24 patients were enrolled to receive 37.5 mg/d of sunitinib for the first 14 days followed by 25 mg/d of sunitinib plus 240 mg nivolumab once every 2 weeks until disease progression or unacceptable toxicity. Imaging reassessments were completed once every 8 weeks. The primary end point was progression-free survival (PFS). Key secondary end points included overall survival (OS), response, and safety.
At a median follow-up of 18 months and among 23 evaluable patients, median PFS was 13.2 months with a 6-month PFS rate of 77%. Median OS was not achieved, and the 12-month OS rate was 90%. The best response was partial response in 2 patients, stable disease in 18 patients, and progression in 2 patients. Median PFS for patients who previously received an antiangiogenic agent was 7 months (P = .11) and OS was 28 months (P = .038). The most common grade 3/4 adverse events occurring in > 5% of patients included hypertension (29.2%), ALT increase (16.7%), AST increase (12.5%), bilirubin increase (12.5%), and lymphocytopenia (12.5%).
“The combination of sunitinib and nivolumab has shown to be active in advanced extraskeletal myxoid chondrosarcoma,” concluded Dr Hindi et al. “Our data suggest that using this combo in upfront lines provides a greater benefit.”
Source:
Hindi N, Palmerini E, Carrasco-Garcia I, et al. Phase II of sunitinib plus nivolumab in extraskeletal myxoid chondrosarcoma: Results from the GEIS, ISG, and UCL IMMUNOSARC II study. Presented at 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract 11513
